lipoxygenase
proteinLipoxygenase catalyzes arachidonic acid oxidation to pro-inflammatory and pro-thrombotic lipid mediators in plaque inflammation.
Pathway placement
Cascade stepPlaque inflammation
Confidencehigh
RationaleArachidonic acid enzyme generating pro-inflammatory and pro-thrombotic lipid mediators.
Also acts inThromboxane / COX-1
Druggability
Not assessed (no mapped human gene target).
Type I vs Type II discrimination
ScoresShared / rises in both
R — rupture / Type-I67
C — confounder / Type-II56
A — assay feasibility68
E — evidence strength42
T1DI (composite)16
Specificity differential (R−C)+11.1
Confounder panel (Type-II drivers)
1sepsis / systemic inflammationmag 2
2anemia / acute blood lossmag 2
3hypovolemia / dehydrationn/a
4tachyarrhythmiamag 1
5hypoxemia / respiratory failuremag 2
6hypertensive emergencymag 2
7high-demand / peri-operative stressmag 1
Coverage: 6/7 confounders with evidence
Tier: deep-scored (abstract-extracted) · 15 supporting references. See the discrimination table for all markers.
Assay & specimen
Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum or plasma
Collection tube
Serum separator (gold/red-top, SST) · K2/K3-EDTA (lavender-top)
Method / principle
Sandwich immunoassay (ELISA) — research-grade unless a cleared assay exists
Reagent / substrate
Matched anti-target antibody pair (capture + labeled detection)
Platform
ELISA microplate or multiplex (Luminex/MSD)
Turnaround · availability
Send-out / research · Research-grade (no universal clinical assay)
Literature evidence(2)
- Restoring perturbed oxylipins with Danqi Tongmai Tablet attenuates acute myocardial infarction.Phytomedicine : international journal of phytotherapy and phytopharmacology · 2021 · PMID 34252738 · doi
- Pharmacogenomics: a tool to prevent and cure coronary heart disease.Current pharmaceutical design · 2007 · PMID 18220812 · doi
Clinical trials(2)
- Role of the Arachidonate 5-Lipoxygenase Pathway in Coronary Heart DiseaseNCT00379808 · NA · COMPLETED · montelukast, Placebo
- A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Effect of VIA-2291, a 5-Lipoxygenase Inhibitor, on Vascular Inflammation in Patients After an Acute Coronary Syndrome EventNCT00552188 · PHASE2 · COMPLETED · VIA-2291, Placebo